RxDoctor Payments Data

Krista Gressette, MD

Internal Medicine · Columbia, SCNPI 1720604838

Payments from drug & device makers

$2,050in general payments, 2019–2025

Across 101 payments — averaging $20.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$523
  • Lilly USA, LLC$337
  • Novo Nordisk$229
  • AbbVie$118
  • Novartis$108
  • Amgen$106
  • plus $628 from 16 others

What the payments were for

  • Food & beverage$2,050100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,050 in reported general payments places this provider in the 75th percentile of 1,498 internal medicine providers in South Carolina.

See all internal medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$91,502
Medicare patients
188
Services billed
2,033

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide21$35,259
OzempicSemaglutide14$13,352
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$10,223
Rosuvastatin Calcium98$1,583
Levothyroxine Sodium93$1,211
Omeprazole51$901
Atorvastatin Calcium86$778
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide21$675
Bupropion XlBupropion Hcl12$569
Pravastatin Sodium25$563
Albuterol Sulfate HfaAlbuterol Sulfate13$557
Gabapentin46$538
Amlodipine Besylate-BenazeprilAmlodipine Besylate/Benazepril18$531
Metoprolol Succinate25$490
Celecoxib21$477

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$337$35,25921 claims
Novo NordiskOzempic$229$13,35214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,498 internal medicine providers in South Carolina.

Other internal medicine in Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →